Top

Published in:

01-12-2003 | Review

Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials

Author: William G. Goodman

Published in: Pediatric Nephrology | Issue 12/2003

Abstract

Calcimimetic agents are small organic molecules that act as allosteric activators of the calcium sensing receptor (CaSR). In parathyroid cells, they lower the threshold for receptor activation by extracellular calcium ions and diminish parathyroid hormone (PTH) secretion. Calcimimetic compounds thus represent a novel way of controlling excess PTH secretion in clinical disorders such as secondary hyperparathyroidism (SHPT) due to chronic renal failure. Clinical trials have documented that the calcimimetic agent cinacalcet hydrochloride effectively lowers plasma PTH levels without increasing serum calcium or phosphorus concentrations in adult hemodialysis patients with SHPT. Serum phosphorus levels and values for the calcium-phosphorus ion product in serum often decline as plasma PTH levels fall during treatment. Experimental evidence suggests that calcimimetic agents may also impede the development of parathyroid gland hyperplasia, an integral component of SHPT due to chronic renal failure. Calcimimetic agents have considerable potential, therefore, as part of new therapeutic strategies for SHPT.

Slatopolsky E, Delmez JA (1994) Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 23:229–236PubMed

Parfitt AM (1997) The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52:3–9PubMed

Mehls O, Wuhl E, Haffner D, Schaefer F, Tonshoff B (1996) Growth hormone treatment of short children with chronic renal failure before and after renal transplantation: rationale and recent results. Nephrol Dial Transplant 11:1747–1750PubMed

Wuhl E, Haffner D, Nissel R, Schaefer F, Mehls O, and German Study Group for Growth Hormone Treatment in Chronic Renal Failure (1996) Short dialyzed children respond less to growth hormone than patients prior to dialysis. Pediatr Nephrol 10:294–298CrossRefPubMed

Chesney RW, Moorthy AV, Eisman JA, Tax DK, Mazess RB, DeLuca HF (1978) Increased growth after long-term oral 1,25-vitamin D₃ in childhood renal osteodystrophy. N Engl J Med 298:238–242PubMed

Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during treatment with intermittent calcitriol and dialysis in children with chronic renal failure. Kidney Int 53:205–211PubMed

Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMed

Dawson-Hughes B (1991) Calcium supplementation and bone loss: a review of controlled clinical trials. Am J Clin Nutr 54:274S–280SPubMed

Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239–297PubMed

10.

Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J (2000) Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57:50–58CrossRefPubMed

11.

Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977–2983PubMed

12.

Nemeth EF (1996) Calcium receptors as novel drug targets. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles in bone biology, 1st edn. Academic Press, San Diego, pp 1019–1035

13.

Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040–4045PubMed

14.

Goodman WG (2001) Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59:1187–1201CrossRefPubMed

15.

Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–617PubMed

16.

Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938–942PubMed

17.

Brown EM (1993) Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens 2:541–551PubMed

18.

Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM (1986) Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78:1296–1301PubMed

19.

Brown EM, Broadus AE, Brennan MF, Gardner DG, Marx SJ, Spiegel AM, Downs RW Jr, Attie M, Aurbach GD (1979) Direct comparison in vivo and in vitro of suppressibility of parathyroid function by calcium in primary hyperparathyroidism. J Clin Endocrinol Metab 48:604–610PubMed

20.

Ramirez JA, Goodman WG, Gornbein J, Menezes C, Moulton L, Segre GV, Salusky IB (1993) Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 76:1489–1494PubMed

21.

Antonsen JE, Sherrard DJ, Andress DL (1998) A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223–227CrossRefPubMed

22.

Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436–445CrossRefPubMed

23.

Yamaguchi T, Chattopadhyay N, Kifor O, Ye C, Vassilev PM, Sanders JL, Brown EM (2001) Expression of extracellular calcium-sensing receptor in human osteoblastic MG-63 cell line. Am J Physiol Cell Physiol 280:C382–C393PubMed

24.

Yamaguchi T, Kifor O, Chattopadhyay N, Brown EM (1998) Expression of extracellular calcium (Ca2+o)-sensing receptor in the clonal osteoblast-like cell lines, UMR-106 and SAOS-2. Biochem Biophys Res Commun 243:753–757CrossRefPubMed

25.

Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW (2002) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017–1024PubMed

26.

Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus product levels in hemodialysis patients with secondary hyperparathyroidism. Kidney Int 63:248–254CrossRefPubMed

27.

Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575–583PubMed

28.

Drüeke T, Cunningham J, Goodman WG, Horl WH, Braun J, Chen M-G, McCary LC, Steinhauslin-Jeanrenaud F, Turner SA, Ritz E (2001) Short-term treatment of secondary hyperparathyroidism with the calcimimetic agent AMG 073. J Am Soc Nephrol 12:764

Title: Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials
Author: William G. Goodman
Publication date: 01-12-2003
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 12/2003
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-003-1290-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2003

Suggested management of immunocompromized kidney patients suffering from SARS

Vesicoureteral reflux in infants with isolated antenatal hydronephrosis

ACE-inhibitors-induced metabolic acidosis in a child with nephrotic syndrome

Parathyroid hormone and its fragments in children with chronic renal failure

Possible role of new pressor protein in hypertensive anephric hemodialysis patients

The effects of corticosteroids on behavior in children with nephrotic syndrome